# obesity FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/obesity

> 27 upcoming FDA catalysts in obesity: nimacimab (SKYE) on November 2026 (primary completion); maridebart cafraglutide (AMGN) on Jan to Apr 2027 (topline data readout); maridebart cafraglutide (AMGN) on January 2027 (primary completion); cagrisema (cagrilintide b and semaglutide i, NVO) on March 2027 (primary completion); and 23 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2023 | [VK2735 trial start](https://sec-api.dev/pdufa/vk2735) | VKTX | obesity | completed | "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)) |
| Sep 2024 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA | obesity | completed, positive | "In September 2024, we announced positive top-line data from the" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1638287/000155837025003386/mtva-20241231x10k.htm)) |
| Jun 2025 | [Wegovy (semaglutide) trial start](https://sec-api.dev/pdufa/semaglutide) | NVO | obesity | completed | "In June 2025, Novo Nordisk initiated a phase 3b trial, REDEFINE 11, for CagriSema in people living with obesity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025038087/caq22025.htm)) |
| June 19, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity | completed | "NCT05931380 (A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931380)) |
| late 2025 | [RT-114 trial start](https://sec-api.dev/pdufa/rt-114) | RANI | obesity | scheduled | "Initiation of Phase 1 clinical trial of RT-114 for the treatment of obesity expected in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/rani-ex99_1.htm)) |
| Q4 2025 | [CRB-913 trial start](https://sec-api.dev/pdufa/crb-913) | CRBP | obesity | scheduled | "For our obesity drug CRB-913, we expect to present SAD/MAD data later this year and to initiate a Phase 1b dose-range finding study in the fourth quarter of 2025."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000095017025102447/crbp-ex99_1.htm)) |
| October 6, 2025 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Obesity | completed | "NCT06804603 (A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804603)) |
| October 15, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT05726227 (A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05726227)) |
| October 23, 2025 | [PF-07976016 primary completion](https://sec-api.dev/pdufa/pf-07976016) | PFE | Obesity | completed | "NCT06717425 (A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717425)) |
| December 8, 2025 | [WVE-007 interim data readout](https://sec-api.dev/pdufa/wve-007) | WVE | obesity | completed, positive | "CAMBRIDGE, Mass., December 8, 2025 - Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave's proprietary SpiNA design, for the treatment of obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/d20484dex991.htm)) |
| December 8, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT06131437 (A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06131437)) |
| December 15, 2025 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | completed | "NCT06373146 (A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06373146)) |
| January 5, 2026 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA | Obesity | completed, positive | "On January 5, 2026, we announced positive topline data of Phase 1 MAD Part 2 non-titrated 48 mg Cohort 5 clinical trial of DA-1726." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm)) |
| April 22, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT06388187 (A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388187)) |
| June 16, 2026 | [Trevogrumab-part a primary completion](https://sec-api.dev/pdufa/trevogrumab-part-a) | REGN | Obesity | completed | "NCT06299098 (A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06299098)) |
| July 20, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity | completed | "NCT05931380 (A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931380?tab=results)) |
| late 2026 | [RaniPill (RT-116) trial start](https://sec-api.dev/pdufa/rt-116) | RANI | obesity | scheduled | "GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd. The study was expanded to enroll fifteen additional healthy volunteers to provide a comprehensive pharmacokinetic dataset for the RaniPill® HC as Rani moves toward initiating a Phase 1b repeat-dose study in patients with obesity by the end of 2026, with data anticipated in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-ex99_1.htm)) |
| September 14, 2026 | [CRB-913 topline data readout](https://sec-api.dev/pdufa/crb-913) | CRBP | obesity | completed, positive | "On September 14, 2026, the Company announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/crbp-20260914.htm)) |
| Q4 2026 | [Nimacimab topline data readout](https://sec-api.dev/pdufa/nimacimab) | SKYE | Obesity | scheduled | "The Company expects its current capital to fund projected operations and key clinical milestones into the fourth quarter of 2026, including topline data from the Phase 2a extension study of nimacimab and certain manufacturing and clinical activities, initial manufacturing runs needed to enable a subsequent trial, and planning activities, but excluding the anticipated clinical cost of a proposed Phase 2b study to evaluate higher doses of nimacimab and support combination development and additional anticipated drug manufacturing costs to resupply any such Phase 2b study." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm)) |
| November 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT06662383 (A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662383)) |
| Nov 2026 to Feb 2027 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT06662383 (A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662383)) |
| November 2026 | [Nimacimab primary completion](https://sec-api.dev/pdufa/nimacimab) | SKYE | Obesity | scheduled | "NCT06577090 (Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Skye Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577090)) |
| Jan to Apr 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity | scheduled | "NCT06858839 (Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858839)) |
| January 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity | scheduled | "NCT06858839 (Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858839)) |
| March 2027 | [Cagrisema (cagrilintide b and semaglutide i) primary completion](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Obesity | scheduled | "NCT07011667 (A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011667)) |
| Mar to Jun 2027 | [Cagrisema (cagrilintide b and semaglutide i) topline data readout](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Obesity | scheduled | "NCT07011667 (A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011667)) |
| May 2027 | [Ribupatide primary completion](https://sec-api.dev/pdufa/ribupatide) | KLRA | Obesity | scheduled | "NCT07458269 (Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Kailera." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07458269)) |
| May to Aug 2027 | [Ribupatide topline data readout](https://sec-api.dev/pdufa/ribupatide) | KLRA | Obesity | scheduled | "NCT07458269 (Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Kailera." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07458269)) |
| Jun to Sep 2027 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT07639021 (A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07639021)) |
| June 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT07639021 (A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07639021)) |
| March 2028 | [Ribupatide primary completion](https://sec-api.dev/pdufa/ribupatide) | KLRA | Obesity | scheduled | "NCT07284979 (Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Kailera." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284979)) |
| Mar to Jun 2028 | [Ribupatide topline data readout](https://sec-api.dev/pdufa/ribupatide) | KLRA | Obesity | scheduled | "NCT07284979 (Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Kailera." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284979)) |
| April 2028 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity | scheduled | "NCT06859268 (A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859268)) |
| Apr to Jul 2028 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity | scheduled | "NCT06859268 (A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859268)) |
| Jun to Sep 2028 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07503210 (AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503210)) |
| June 2028 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07503210 (AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503210)) |
| Aug to Nov 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT06780449 (A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-28 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780449)) |
| August 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT06780449 (A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-28 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780449)) |
| Feb to May 2029 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794774 (A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794774)) |
| February 2029 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794774 (A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794774)) |
| Mar to Jun 2029 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794761 (A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794761)) |
| March 2029 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794761 (A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794761)) |
| Jun to Sep 2029 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07339423 (AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-26 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07339423)) |
| June 2029 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07339423 (AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-26 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07339423)) |
| October 2029 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07881432 (A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881432)) |
| Oct 2029 to Jan 2030 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07881432 (A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881432)) |
| December 2029 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07817875 (Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817875)) |
| Dec 2029 to Mar 2030 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07817875 (Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817875)) |

## Drugs

- [VK2735](https://sec-api.dev/pdufa/vk2735) (VKTX)
- [DA-1726](https://sec-api.dev/pdufa/da-1726) (MTVA)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [RT-114](https://sec-api.dev/pdufa/rt-114) (RANI)
- [CRB-913](https://sec-api.dev/pdufa/crb-913) (CRBP)
- [NEREUSTM (tradipitant)](https://sec-api.dev/pdufa/tradipitant) (VNDA)
- [PF-07976016](https://sec-api.dev/pdufa/pf-07976016) (PFE)
- [WVE-007](https://sec-api.dev/pdufa/wve-007) (WVE)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Trevogrumab-part a](https://sec-api.dev/pdufa/trevogrumab-part-a) (REGN)
- [RaniPill (RT-116)](https://sec-api.dev/pdufa/rt-116) (RANI)
- [Nimacimab](https://sec-api.dev/pdufa/nimacimab) (SKYE)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Cagrisema (cagrilintide b and semaglutide i)](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) (NVO)
- [Ribupatide](https://sec-api.dev/pdufa/ribupatide) (KLRA)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [NNC0487-0111](https://sec-api.dev/pdufa/nnc0487-0111) (NVO)
- [Berobenatide](https://sec-api.dev/pdufa/berobenatide) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/obesity.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "obesity FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/obesity

```bibtex
@misc{secapidev_indications_obesity_20261116,
  title        = {obesity FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/obesity}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_obesity_20261116","title":"obesity FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/obesity","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
